Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants

Journal of Infectious Diseases

Volumn 209, Issue 6, 2014, Pages 887-897

  Lutwama, F ^a,b,c   Kagina, B M ^a,b   Wajja, A ^c   Waiswa, F ^c   Mansoor, N ^a,b   Kirimunda, S ^c   Hughes, E J ^a,b   Kiwanuka, N ^c   Joloba, M L ^c   Musoke, P ^c   Scriba, T J ^a,b   Mayanja Kizza, H ^c   Day, C L ^a,b,d,e   Hanekom, W A ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^d EMORY UNIVERSITY   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

BCG; birth; delayed; Uganda; vaccination

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSAGE SCHEDULE COMPARISON; FEMALE; HUMAN; HUMAN CELL; INFANT; LYMPHOCYTE PROLIFERATION; MALE; NEWBORN; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; UGANDA;

BCG; BIRTH; CD4+ AND CD8+ T-CELL RESPONSES; DELAYED; UGANDA; VACCINATION;

BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOLOGIC MEMORY; INFANT; INFANT, NEWBORN; MALE; UGANDA;

EID: 84895734788     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit570     Document Type: Article

References (50)

1. Fine PE, Carneiro IAM, Milstien JB. Issues relating to the use of BCG immunisation programmes. WHO/V&B/99.23. Geneva: World Health Organization, 1999.
2. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a metaanalysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-80.
3. Aaby P, Roth A, Ravn H, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011; 204:245-52.
4. World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec 2004; 79:27-38.
5. World Health Organization. WHO global tuberculosis control. 2011.
6. Fadnes LT, Nankabirwa V, Sommerfelt H, Tylleskar T, Tumwine JK, Engebretsen IM. Is vaccination coverage a good indicator of age-appropriate vaccination? A prospective study from Uganda. Vaccine 2011; 29:3564-70.
7. Nankabirwa V, Tumwine JK, Tylleskar T, Nankunda J, Sommerfelt H. Perinatal mortality in eastern Uganda: a community based prospective cohort study. PLoS One 2011; 6:e19674.
8. Ministry of Health, Uganda. Promotion of Immunisation in Uganda: Booklet for Leaders. Vaccine Resource Library 2002. http:\\www.path.org/ vaccineresources/files/Uganda-immunisation-advocacy.pdf. Accessed 11 November 2013.
9. Hoft DF, Blazevic A, Stanley J, et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCGinduced human immunity. Vaccine 2012; 30:2098-108.
10. Murray RA, Mansoor N, Harbacheuski R, et al. Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response. J Immunol 2006; 177:5647-51.
11. Smith SM, Malin AS, Pauline T, et al. Characterization of human Mycobacterium bovis bacille Calmette-Guerin-reactive CD8+ T cells. Infect Immun 1999; 67:5223-30.
12. Soares AP, Scriba TJ, Joseph S, et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008; 180:3569-77.
13. Semple PL, Watkins M, Davids V, et al. Induction of granulysin and perforin cytolytic mediator expression in 10-week-old infants vaccinated with BCG at birth. Clin Dev Immunol 2011; 2011:438463.
14. Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010; 182:1073-9.
15. Corbett NP, Blimkie D, Ho KC, et al. Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One 2010; 5:e15041.
16. Sadeghi K, Berger A, Langgartner M, et al. Immaturity of infection control in preterm and term newborns is associated with impaired tolllike receptor signaling. J Infect Dis 2007; 195:296-302.
17. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science 2002; 296:490-4.
18. Burl S, Adetifa UJ, Cox M, et al. Delaying bacillus Calmette-Guerin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J Immunol 2010; 185:2620-8.
19. Hussey GD, Watkins ML, Goddard EA, et al. Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies. Immunology 2002; 105:314-24.
20. Marchant A, Goetghebuer T, Ota MO, et al. Newborns develop a Th1- type immune response to Mycobacterium bovis bacillus Calmette- Guerin vaccination. J Immunol 1999; 163:2249-55.
21. Kagina BM, Abel B, Bowmaker M, et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine 2009; 27:5488-95.
22. Hanekom WA, Hughes J, Mavinkurve M, et al. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J Immunol Methods 2004; 291:185-95.
23. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997; 99:1739-50.
24. Soares A, Govender L, Hughes J, et al. Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J Immunol Methods 2010; 362:43-50.
25. Roederer M, Nozzi JL, Nason MX. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011; 79A:167-74.
26. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12.
27. Rook GA. Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med 2007; 7:327-37.
28. Schreiber T, Ehlers S, Heitmann L, et al. Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity. J Immunol 2009; 183:1301-12.
29. Combadiere B, Boissonnas A, Carcelain G, et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004; 199:1585-93.
30. Gerdes J, Lemke H, Baisch H,Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133:1710-5.
31. Cellerai C, Harari A, Vallelian F, Boyman O, Pantaleo G. Functional and phenotypic characterization of tetanus toxoid-specific human CD4 + T cells following re-immunization. Eur J Immunol 2007; 37:1129-38.
32. Bogunovic D, Byun M, Durfee LA, et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science 2012; 337:1684-8.
33. Ottenhoff TH, de Boer T, Verhagen CE, Verreck FA, van Dissel JT. Human deficiencies in type 1 cytokine receptors reveal the essential role of type 1 cytokines in immunity to intracellular bacteria. Microbes Infect 2000; 2:1559-66.
34. Thiery J, Keefe D, Boulant S, et al. Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nat Immunol 2011; 12:770-7.
35. Rahman S, Magalhaes I, Rahman J, et al. Prime-boost vaccination with rBCG/rAd35 enhances CD8(+) cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates.Mol Med 2012; 18:647-58.
36. Harari A, Vallelian F, Pantaleo G. Phenotypic heterogeneity of antigenspecific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol 2004; 34:3525-33.
37. Soares AP, Kwong Chung CK, Choice T, et al. Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis 2013; 207:1084-94.
38. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment- specific lymphocyte homing. Curr Opin Immunol 2000; 12:336-41.
39. Pitt JM, Stavropoulos E, Redford PS, et al. Blockade of IL-10 signaling during bacillus Calmette-Guerin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-gamma and IL-17 responses and increases protection to Mycobacterium tuberculosis infection. J Immunol 2012; 189:4079-87.
40. Forbes EK, Sander C, Ronan EO, et al. Multifunctional, high-level cytokine- producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008; 181:4955-64.
41. Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010; 181:1407-17.
42. Sander CR, Pathan AA, Beveridge NE, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis- infected individuals. Am J Respir Crit Care Med 2009; 179:724-33.
43. Scriba TJ, Tameris M, Smit E, et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosisinfected adults. Am J Respir Crit Care Med 2012; 185:769-78.
44. Rodriguez L, Gonzalez C, Flores L, Jimenez-Zamudio L, Graniel J, Ortiz R. Assessment by flow cytometry of cytokine production in malnourished children. Clin Diagn Lab Immunol 2005; 12:502-7.
45. Ota MO, Odutola AA, Owiafe PK, et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 2011; 3:88ra56.
46. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008; 26:2350-9.
47. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-93.
48. Black GF, Thiel BA, Ota MO, et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol 2009; 16:1203-12.
49. Elias D, Wolday D, Akuffo H, Petros B, Bronner U, Britton S. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guerin (BCG) vaccination. Clin Exp Immunol 2001; 123:219-25.
50. Shey MS, Randhawa AK, Bowmaker M, et al. Single nucleotide polymorphisms in toll-like receptor 6 are associated with altered lipopeptide- and mycobacteria-induced interleukin-6 secretion. Genes Immun 2010; 11:561-72. Partnership